Insights From Technical Analysis
Has Neurizon Therapeutics (ASX: NUZ) Formed a Sustainable Long-Term Floor at Its Multi-Year Support Base?
Neurizon Therapeutics (ASX: NUZ) is a clinical-stage biotech developing NUZ-001 for ALS and other neurodegenerative diseases. Despite promising data and global trials, the stock faces pressure from clinical delays, dilution, rising losses, and ongoing uncertainty typical of pre-revenue biotech companies.
Haranga Resources (ASX: HAR) Rockets Higher as Gold Discovery Frenzy Ignites Massive Share Price Volatility
Haranga Resources has seen sharp volatility driven by renewed excitement around its Lincoln Gold Project in the US, with drilling results and expected JORC resource updates fueling speculation. The company remains an early-stage explorer, heavily dependent on exploration success, making its share price highly sensitive to news flow and gold sentiment.
Minbos Resources (ASX: MNB) Explodes Higher as Funding Breakthrough Sparks Massive Share Price Surge
Minbos Resources surged after securing US$21.5 m+ in debt funding for its Cabinda Phosphate Project in Angola, boosting investor confidence in its move toward production. The market now eyes construction progress, though execution, funding, and ramp-up risks remain significant.
Is Elevra Lithium (ASX: ELV) Ready to Break Through Key Resistance?
Elevra Lithium (ASX: ELV) is a dual-listed North American-focused producer with growth assets, led by its Québec NAL operation. Recent share moves reflect capital raising, record production, index inclusion, improving lithium sentiment, while technicals show an uptrend nearing key resistance.
Imugene (ASX: IMU) Roars Back to Life as Explosive Share Price Rebound Sparks Fresh Speculative Buzz
Imugene (ASX: IMU) surged over 35% after early Azer-cel trial results showed strong response rates in blood cancer patients, reigniting biotech speculation. Despite the rally, the stock remains highly volatile and pre-revenue, with future moves dependent on clinical progress, funding needs, and upcoming ASCO updates.
Has Galan Lithium (ASX: GLN) Built a Durable Base for Its Next Leg Higher?
Galan Lithium (ASX: GLN) is an Australian developer focused on high-grade lithium brine projects in Argentina, led by Hombre Muerto West. It is advancing toward production, supported by strong lithium prices, funding, and expansion, though dilution and execution risks remain.